Title | Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Lage, C, Suarez, AGonzalez, Pozueta, A, Riancho, J, Kazimierczak, M, Bravo, M, Bonilla, JJimenez, Torres, Mde Arcocha, Quirce, R, Banzo, I, Vázquez-Higuera, JLuis, Rabinovici, GD, Rodriguez-Rodriguez, E, Sánchez-Juan, P |
Journal | J Alzheimers Dis |
Volume | 63 |
Issue | 3 |
Pagination | 1025-1033 |
Date Published | 2018 |
ISSN | 1875-8908 |
Abstract | The clinical utility of amyloid positron emission tomography (PET) has not been fully established. Our aim was to evaluate the effect of amyloid imaging on clinical decision making in a secondary care unit and compare our results with a previous study in a tertiary center following the same methods. We reviewed retrospectively 151 cognitively impaired patients who underwent amyloid (Pittsburgh compound B [PiB]) PET and were evaluated clinically before and after the scan in a secondary care unit. One hundred and fifty concurrently underwent fluorodeoxyglucose (FDG)-PET. We assessed changes between the pre- and post-PET clinical diagnosis and Alzheimer's disease treatment plan. The association between PiB/FDG results and changes in management was evaluated using χ2 and multivariate logistic regression. Concordance between classification based on scan readings and baseline diagnosis was 66% for PiB and 47% for FDG. The primary diagnosis changed after PET in 17.2% of cases. When examined independently, discordant PiB and discordant FDG were both associated with diagnostic change (p |
DOI | 10.3233/JAD-170985 |
Alternate Journal | J. Alzheimers Dis. |
PubMed ID | 29710706 |